Astex Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Astex Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Astex Pharmaceuticals Inc Strategy Report
- Understand Astex Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Astex Pharmaceuticals Inc (Astex Pharmaceuticals), a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. It is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.
Headquarters
United States of America
Address
Suite 200, 4420 Rosewood Drive, Pleasanton, California, 94588
Website
astx.com
Telephone
1 925 5600100
Industry
Pharmaceuticals and Healthcare
Astex Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Guadecitabine (SGI-110) - Hematologic Malignancies and Solid Tumors |
| ASTX660 - Dual IAP Antagonist for Solid Tumors |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In November, the company entered into an agreement with Faslodex for the treatment of adult patients with HR-positive, HER2-negative locally advanced, metastatic breast cancer with one or more biomarker alterations. |
| 2023 | Contracts/Agreements | In February, the company and Cardiff University Medicines Discovery Institute announced their collaboration on new drug discovery for Neurodegenerative Diseases. |
| 2022 | Others | In January, the company was granted Orphan Drug Designation by the European Comission for oral dectabine and cedauridine (ASTX727). |
Competitor Comparison
| Key Parameters | Astex Pharmaceuticals Inc | Vertex Pharmaceuticals Inc | Exelixis Inc | Infinity Pharmaceuticals Inc | Morvus Technology Ltd |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United Kingdom |
| City | Pleasanton | Boston | Alameda | Cambridge | Brecon |
| State/Province | California | Massachusetts | California | Massachusetts | Powys |
| No. of Employees | - | 5,400 | 1,310 | 30 | 1 |
| Entity Type | Private | Public | Public | Public | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Harren Jhoti | President - Astex Pharmaceuticals UK; Chief Executive Officer - Astex Pharmaceuticals UK | Executive Board | - | - |
| Harold N. Keer | Chief Medical Officer | Senior Management | 2020 | - |
| Nipun Davar | Chief Corporate Officer | Senior Management | - | - |
| David Rees | Chief Scientific Officer - UK | Senior Management | - | - |
| Martin Buckland | President | Executive Board | 2020 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward